Bacterial Biofilms, Responsible for Up to 75% of All Infectious Diseases in America, Explored in New Webinar From Quidel Corporation

SAN DIEGO–(BUSINESS WIRE)–#LymeDisease–The National Institutes of Health reports that bacterial biofilms are responsible for up to 75% of all infectious diseases in humans, including infections of wounds, the lungs and the urinary tract. This important medical reality is now being addressed in a new webinar made available by Quidel Corporation, the California-based diagnostic health care … [Read more…]

Ranok Therapeutics Announces Initiation of Patient Dosing in a Phase 1/2 Clinical Trial of RNK05047, a First-in-Class BRD4-Targeting CHAMP™ Protein Degrader

Study will evaluate the first protein degrader developed using Ranok’s innovative CHAMP™ technology in patients with advanced solid tumors or diffuse large B-cell lymphoma (DLBCL) BOSTON & HANGZHOU, China–(BUSINESS WIRE)–Ranok Therapeutics, a clinical-stage biopharmaceutical company that is developing a novel approach to targeted protein degradation for the treatment of cancer and other serious diseases, today … [Read more…]

Glaukos Announces Participation in the Wells Fargo Healthcare Conference

ALISO VIEJO, Calif.–(BUSINESS WIRE)–Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 7, 2022, at 3:45 p.m. ET in Boston, MA. … [Read more…]

Nimbus Therapeutics Presents New Data on Oral Allosteric TYK2 Inhibitor at American Chemical Society Meeting

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Nimbus Therapeutics, a clinical-stage company that is working to design and develop breakthrough medicines through its powerful computational drug discovery engine, today presented research describing the chemical structure of NDI-034858, the company’s investigational oral allosteric TYK2 (tyrosine kinase 2) inhibitor now in two Phase 2b clinical studies for moderate-to-severe plaque psoriasis and active … [Read more…]

Oragenics Announces Favorable Preliminary Toxicology Data for Intranasal COVID-19 Vaccine Candidate

N T-CoV2-1 preliminary data supports regulatory filings for Phase 1 studies Intranasal administration elicits immune responses TAMPA, Fla.–(BUSINESS WIRE)–Oragenics, Inc. (NYSE American: OGEN) (“Oragenics” or the “Company”), a biotech company dedicated to fighting infectious diseases including COVID-19, today announced favorable preliminary results from its ongoing Good Laboratory Practice (GLP) toxicology study to evaluate the safety profile … [Read more…]

AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022

Results will further underscore efficacy and safety of IMFINZI®, TAGRISSO®, and LYNPARZA® across multiple cancers with high unmet need ENHERTU data will reinforce its transformative potential in HER2-targetable cancers New data for MEDI5752 will advance the science of next-generation immunotherapy WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca will present new data supporting its ambition to redefine cancer care at … [Read more…]

Mednow Signs Franchise Agreement to Open Quebec Pharmacy

Mednow’s Quebec location serves all of Quebec with its pharmacy delivery distribution center plus virtual and in person patient consultation space. TORONTO & SAINT-LAURENT, Quebec–(BUSINESS WIRE)–Mednow Inc. (“Mednow” or the “Company”) (TSXV:MNOW) (OTCQX:MDNWF) Canada’s on-demand virtual pharmacy, is officially open to serve patients in Quebec. This newest Mednow location will serve as the pharmacy distribution … [Read more…]

SaNOtize Announces $24 Million in Series B Funding to Advance Its Nitric Oxide-Based Therapeutics, Including Nasal Spray for the Treatment and Prevention of COVID-19

Co-led by Horizons Ventures and OurCrowd, new funding enables SaNOtize to invest in its ongoing Phase 3 clinical trial for COVID-19 prevention and enhance clinical development of its other nitric oxide-based therapeutics SaNOtize’s Nitric Oxide Nasal Spray (NONS™) has been clinically shown to treat COVID-19 in high-risk adult patients and to prevent infections when used … [Read more…]

Critical Insight Finds Attackers Shifting Focus to Smaller Hospital Systems and Specialty Clinics in H1 2022 Healthcare Data Breach Report

SEATTLE–(BUSINESS WIRE)–Critical Insight, a Managed Detection and Response (MDR) service provider specializing in protecting the networks of life-saving organizations and critical infrastructure, announced today the release of the firm’s H1 2022 Healthcare Data Breach Report, which analyzes ​​breach data reported to the U.S. Department of Health and Human Services by healthcare organizations. With the healthcare … [Read more…]

United Therapeutics to Feature Clinical Data at the European Society of Cardiology Congress 2022 and the European Respiratory Society International Congress 2022

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.–(BUSINESS WIRE)–United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that four posters and one oral presentation will be presented at the European Society of Cardiology (ESC) Congress 2022, taking place August 26-29, 2022, and the European Respiratory Society (ERS) International Congress 2022, taking place September … [Read more…]